Biotech dealmaking accelerated heading into the JPM 2026 Healthcare Conference as large drugmakers face looming patent cliffs and hunt for growth. Five therapeutic categories are absorbing most strategic capital: radiopharmaceuticals, next-gen GLP-1, autologous CAR-T, allogeneic cell therapy, and antibody-drug conjugates. Below are the publicly traded category leaders in each. Each is a well-positioned standalone business with M&A optionality, not a takeout prediction.
5. ADC Therapeutics: Pure-Play ADCs
ADC Therapeutics (NYSE: ADCT) is one of the few remaining pure-play, commercial-stage ADC names after Pfizer paid $43 billion for Seagen and AbbVie bought ImmunoGen. Lead drug Zynlonta generated $20.03 million in Q1 2026 net product revenue, up 15% year over year, and Q1 revenue of $20.85 million beat the consensus estimate.
The major catalyst is LOTIS-5 Phase 3 topline data expected in Q2 2026, with peak U.S. revenue potential pegged at $600 million to $1 billion and cash runway into 2028. Risks include negative shareholders’ equity of $216.4 million, a Portnoy Law Firm investigation announced in April 2026 over LOTIS-7 safety, and Redmile Group disposing roughly 5.9 million shares in early April 2026. Shares trade near $3.50 apiece.
4. Allogene Therapeutics: Off-the-Shelf CAR-T
Allogene Therapeutics (NASDAQ: ALLO) leads the allogeneic CAR-T category that big pharma views as the manufacturing solution to the scalability challenges of patient-specific autologous therapy. The ALPHA3 interim analysis showed 58.3% measurable residual disease (MRD) clearance, versus 16.7% in the observation arm, with no cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, or graft-versus-host disease. Q1 EPS met expectations at −$0.18, and an April 2026 raise of $200.4 million (gross) extended the runway into Q1 2029.
The challenge is scale. The market cap is roughly $803.9 million, the stock trades near $2.30, and shares are down 23.9% over the past month after the dilutive offering. Long-dated catalysts (interim EFS mid-2027) keep this in the higher-risk bucket.
3. Legend Biotech: The Autologous Powerhouse
Legend Biotech (NASDAQ: LEGN | LEGN Price Prediction) anchors the autologous CAR-T category through its heavyweight partnership with Johnson & Johnson. In recent clinical updates, Carvykti demonstrated a 99% overall response rate (ORR) and 86% complete response/stringent complete response in the CARTITUDE-4 study, with a 94% MRD negativity rate that underscores its “best-in-class” efficacy.
Financial momentum is equally robust: Carvykti generated $597 million in Q1 2026 net trade sales, a 62% year-over-year increase. With a cash position of approximately $1.3 billion and a runway extending through 2026 profitability, Legend has largely de-risked its balance sheet. However, some risks persist, including high operational expenses related to the massive Obelisc manufacturing expansion. Shares are trading for more than $28.00 after a 62.1% rally in the past month, driven by those blowout sales figures and renewed acquisition speculation.
2. Viking Therapeutics: Next-Gen GLP-1
Viking Therapeutics (NASDAQ: VKTX) is the most-named independent in obesity. VK2735 is a dual GLP-1/GIP agonist with VANQUISH-1 fully enrolled (about 4,500 patients) ahead of schedule, and oral VK2735 produced up to 12.2% mean weight reduction at 13 weeks in Phase 2. Phase 2 VENTURE data appeared in the journal Obesity in January 2026.
Polymarket currently prices a 59.5% implied probability of Viking being acquired before 2027, though that figure reflects thin-volume prediction-market sentiment and should be interpreted cautiously. The consensus analyst target stands at $92.33, well above the current share price of approximately $31.50. Risks include a FY2025 net loss of $359.64 million and a Q4 EPS miss of −$1.38 versus the −$0.8958 consensus.
1. Lantheus: Radiopharmaceuticals
Lantheus Holdings (NASDAQ: LNTH) tops the list as the only profitable, commercial-scale name beating expectations every quarter. Q1 2026 revenue of $377.33 million exceeded the $354.42 million consensus by 6.46%, and adjusted EPS of $1.46 beat the $1.2292 estimate by 18.78%. Definity grew 6.8%, and Neuraceq added $35.44 million, partially offsetting Pylarify’s 6.5% year-over-year decline.
Management reaffirmed FY2026 revenue guidance of $1.40 billion to $1.45 billion and adjusted EPS of $5.00 to $5.25, and the company secured FDA approval for Pylarify TruVu ahead of a planned Q4 2026 phased launch. CEO Mary Anne Heino said the team is “laying the groundwork for growth acceleration beginning in 2027.” Shares are up 44.9% year to date to around $96.50 and trade at a 23x trailing P/E. The SPECT business sale closed in January 2026, sharpening focus on radiopharma—a space where Novartis has built a franchise around Pluvicto.
A Framework for Retail Investors
Buying biotech purely on takeout hopes is a coin flip. The cleaner approach is owning category leaders whose standalone fundamentals justify the position, with M&A optionality as a free call. Lantheus offers the strongest standalone profile; Viking, Legend, Allogene, and ADC Therapeutics carry higher clinical and dilution risk for bigger asymmetric payoffs. Position sizing matters most, because biotech drawdowns can be severe and unforgiving.
Top Gaining Stocks
Top Losing Stocks